raised triglycerides and residual cardiovascular risk
|
|
- Marylou Chandler
- 5 years ago
- Views:
Transcription
1 EARN 3 FREE CPD POINTS cardiovascular Leader in digital CPD for Southern African healthcare professionals Prof Dirk Blom University of Cape Town Heart Centre and Lipid Clinic Groote Schuur Hospital raised triglycerides and residual cardiovascular risk Introduction A broader view of the clinical entity of hypertriglyceridaemia is essential to developing an understanding of how triglyceride-rich lipoproteins contribute to overall cardiovascular risk. Despite effective lowering of LDL cholesterol, not all cardiovascular events are prevented. This residual risk has once again focused attention on hypertriglyceridaemia and the contribution that triglyceride-rich lipoproteins and their remnants make to atherosclerosis. 1 Definition of hypertriglyceridaemia While there are a number of definitions of hypertriglyceridaemia, a simplified definition provides a convenient basis for clinical action (Table 1). Table 1. Simplified definition of hypertriglyceridaemia Normal: triglyceride concentration <2.0mmol/L Mild-to-moderate: mmol/L Severe: >.0mmol/L It is important to understand what the laboratory is actually measuring when they report serum triglycerides. Serum triglyceride levels reflect the sum of the triglyceride content of all lipoproteins. The major contributors to serum triglycerides are chylomicrons (CM - present after meals) and very low density lipoproteins (VLDL). LDL and HDL only contribute a small percentage of the total serum triglyceride content. The triglyceride-rich lipoproteins are therefore CM, VLDL and their remnants. Understanding the mechanism of hypertriglyceridaemia It is useful to have a basic understanding of triglyceride-rich lipoprotein (TGRL) metabolism, as illustrated in Figure 1. CM remnants Apo C Apo E Apo B-48 Exports Apo B-0 VLDL HDL Small intestine HDL Apo B-48 CM LPL Liver LPL Apo E LDLR HTGL? Apo B-0 NEFA Apo B-0 Apo C VLDL remnants This report was made possible by an unrestricted educational grant from Cipla. The content of the report is independent of the sponsor. Apo A-1 Figure 1. Understanding TGRL Mechanism: Metabolic pathway of chylomicrons, VLDL and remnant lipoproteins after fat intake. Simplified from: Nakajima K. Remnant Lipoproteins: A Subfraction of Plasma Triglyceride-Rich Lipoproteins Associated with Postprandial Hyperlipidemia. Clin Exp Thromb Hemost 2014; 1(2): DOI: LDL Abbreviations: LPL Lipoprotein Lipase; CM chylomicrons; NEFA Nonesterified fatty acids; VLDL Very low density lipoprotein; HDL High density lipoprotein; LDL Low density lipoprotein November 2018 I 1
2 Briefly, when a fatty meal is ingested, dietary triglycerides are incorporated into CMs which transport lipids from the intestine to the circulation. In the circulation some of the triglyceride content of CM is hydrolysed by lipoprotein lipase (LPL), leading to the formation of CM remnants. CM remnants are taken up by the liver. The liver exports dietary and endogenously synthesised triglycerides in VLDL particles. VLDL particles undergo LPL-mediated lipolysis in the circulation leading to the formation of VLDL remnants; which can either be further metabolised to LDL particles or be taken up by hepatic receptors. Multiple mechanisms may lead to hypertriglyceridaemia. One mechanism is overproduction of CMs and/or VLDL. Triglyceride-rich lipoproteins may be overproduced in patients consuming a high fat diet or when medications or alcohol stimulate hepatic VLDL production. Diabetes is also commonly associated with overproduction of VLDL due to high levels of circulating free fatty acids. Impaired clearance is another important mechanism leading to hypertriglyceridaemia and can be seen in conditions such as ageing, hypothyroidism and genetic disorders. A combination of overproduction and impaired clearance is common in most patients with raised triglycerides. Genetic basis of hypertriglyceridaemia Monogenic hypertriglyceridaemia is rare (one in one million). It usually displays classic autosomal recessive inheritance with high levels of triglycerides (>mmol/l) from birth and is typically managed within specialist lipid clinics. Polygenic hypertriglyceridaemia causes moderate to severely elevated triglyceride levels and usually results from an accumulation of deleterious polymorphisms in many genes in the presence of a second factor, such as a metabolic precipitant. A metabolic precipitant (e.g. becoming diabetic, increased alcohol intake, treatment with steroids or protease inhibitors) may trigger the development of hypertriglyceridaemia (Table 2). 1 Table 2. Secondary causes of hypertriglyceridaemia 1 Obesity Metabolic syndrome Diet with high positive energy-intake balance; and high fat or high glycaemic index Increased alcohol consumption* Diabetes (mainly type 2 diabetes) Hypothyroidism Renal disease (proteinuria, uraemia, or glomerulonephritis) Pregnancy (particularly in the third trimester) Earn free CPD Points Join our CPD community at and start to earn today! Paraproteinaemia Systemic lupus erythematosus Drugs including corticosteroids, oral oestrogen, tamoxifen, thiazides, non-cardioselective β-blockers and bile acid sequestrants, cyclophosphamide, asparaginase, protease inhibitors, and second-generation antipsychotic drugs (e.g. clozapine and olanzapine). *Although the range is variable, the clinical risk of hypertriglyceridaemia is generally thought to increase with more than two units daily for men, and more than one unit daily for women. 2 I November 2018
3 Complications of severe hypertriglyceridaemia In patients with triglyceride levels >-15mmol/L, the focus of care is directed to prevention of acute pancreatitis. Severe hypertriglyceridaemia should be viewed as a medical emergency requiring urgent intervention. In South Africa, alcohol abuse is the major cause of pancreatitis followed by gallstones and then, as a third major cause, severe hypertriglyceridaemia. The advent of pancreatitis is unfortunately poorly predictable; some patients never develop pancreatitis despite very high levels of triglycerides (>50mmol/L). Others may develop acute pancreatitis at much lower triglyceride levels. Patients with hypertriglyceridaemia are also at increased risk of cardiovascular disease. For example, in the Copenhagen Triglycerides, mmol/l Women No. of Participants No. of Events Adjusted for Age Figure 2. Hazard ratios for myocardial infarction, ischaemic heart disease, and total death by increasing levels of non-fasting triglycerides. From the Copenhagen Heart Study 2 p for Trend Adjusted Multifactorially Myocardial Infaction < <.001 < Ischemic Heart Disease < <.001 < Total Death < <.001 < Men Myocardial Infaction < <.001 < Ischemic Heart Disease < < Total Death < <.001 < p for Trend November 2018 I 3
4 Heart Study, 2 patients were divided into cohorts of non-fasting triglyceride levels. Results clearly show that as triglyceride values increased, the risk of myocardial infarctions and ischaemic heart disease events also increased (Figure 2). It is important to note that triglycerides are a surrogate marker for remnant cholesterol which is highly atherogenic. The role that TGRL remnants may play in the pathophysiology of atherosclerosis is shown in Figure 3. 2 Figure 3. Pathophysiology of atherosclerosis. 3 Earn free CPD Points Join our CPD community at Management of severe hypertriglyceridaemia The general principle of managing patients with severe hypertriglyceridaemia is to identify and control precipitating secondary causes (Table 2). Treatment includes restriction of all dietary fat intake, exercise and weight loss; with fibrates as the first line of therapy. In South Africa fenofibrate and bezafibrate are the most commonly used fibrates. Statins are generally not effective as primary therapy. Although niacin and high doses (3-4g/day) of omega-3 polyunsaturated fatty acids (fish oils) can reduce triglycerides, they are more effective in treating moderate hypertriglyceridaemia. Additionally, niacin therapy is associated with significant side-effects (especially worsening of glycaemia) and niacin has failed to show a beneficial effect on cardiovascular outcomes. Omega-3 fatty acids are often expensive, and preparations of sufficient purity are not always available. If there is no clear precipitating cause (e.g. the patient is lean, non-diabetic and not taking any drugs that may precipitate hypertriglyceridaemia), referral to a lipid clinic is advised as this patient may either have a monogenic form of hypertriglyceridaemia or an unusual cause of hypertriglyceridaemia, such as autoantibodies to proteins involved in lipolysis. Several new therapies are currently being investigated for management of severe hypertriglyceridaemia. Antisense oligonucleotides directed against ApoCIII have entered phase 3 clinical trials. and start to earn today! 4 I November 2018
5 Management of moderate hypertriglyceridaemia Patients with triglyceride levels between 2-mmol/L are seen much more commonly in general practice. How to treat high cardiovascular risk patients with residual hypertriglyceridaemia despite adequate statin treatment is a clinical question that is not yet fully answered. Several ongoing clinical trials, such as the STRENGTH study and REDUCE-IT, are focusing on high-dose omega-3 fatty acids added to statins, while another trial (PROMINENT) is evaluating addition of a novel fibrate to statin-based therapy. Figure 4 illustrates the potential role that treating high triglycerides (and thus remnant cholesterol) may play in reducing residual risk. Although both patients have identical levels of LDL cholesterol, the second patient has moderate hypertriglyceridaemia and high estimated remnant cholesterol. 52 year old man Previous ACS with stent to LAD Atorvastatin 80mg/d Non HDLC = 2.0 Estimated remnant cholesterol 1.0 Non HDLC = 2.5 Estimated remnant cholesterol 1.5 TG 1.1 TC 3.0 HDL 1.0 LDL 1.0 TG 3.4 TC 3.3 HDL 0.8 LDL 1.0 Figure 4. Residual risk Because both patients are at very high risk (previous ACS with stent), statin therapy must be optimised and high-intensity statin therapy is required (atorvastatin 40-80mg or rosuvastatin 20-40mg daily). Evidence for adding a fibrate to statinbased therapy is based currently only on a sub-analysis of the ACCORD trial. 5 This post hoc sub-analysis evaluated patients with high triglycerides and low HDL at baseline and showed that addition of a fibrate to simvastatin may reduce cardiovascular event rates in this subgroup. Earlier studies of fibrate monotherapy have been re-evaluated by creating similar high triglyceride and low HDL cholesterol subgroups; and have also shown cardiovascular event reduction with fibrate therapy in these specific subgroups. Currently however, there is not enough evidence for unequivocal guideline recommendations on how patients with moderate hypertriglyceridaemia on adequate statin therapy should be treated. The current EAS/ESC guideline states that one may consider adding fenofibrate in patients receiving adequate statin therapy who have triglycerides >2.3mmol/L (Class IIB, Level C). These patients should ideally be referred to a physician/other specialist to evaluate the benefit/risk of added therapy, Dr Blom concluded. He added that this advice may change in the next few years as further evidence emerges from current trials. November 2018 I 5
6 Summary of major conclusions Earn free CPD Points Are you a member of Southern Africa s leading digital Continuing Professional Development website earning FREE CPD points with access to best practice content? Only a few clicks and you can register to start earning today Visit For all Southern African healthcare professionals What are the known knowns? Recommended action is summarised in Table 3. This conclusion stresses that LDL cholesterol should be treated aggressively. In severe hypertriglyceridaemia, fibrate therapy is first-line therapy to prevent pancreatitis. In patients with moderate hypertriglyceridaemia, fibrates can be considered after achieving LDL cholesterol control and lifestyle intervention. Supporting this approach is the recent announcement of top-line results from the doubleblind, randomised, placebo-controlled REDUCE-IT trial. This trial showed that treatment for a median duration of 4.9 years with high-dose EPA (4g/day) results in a 25% reduction in MACE in statin treated patients with raised triglycerides (entry criteria 1.7 to 5.63mmol/L; observed median at baseline 2.44mmol/L) References 1. Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis and management. Lancet Diabetes Endocrinol 2014; 2(8): Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women. JAMA. 2007; 298(3): Watts GF, Ooi EM, Chan DC. Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol. and a previous cardiovascular event or diabetes with at least one additional cardiac risk factor. The median LDL cholesterol at baseline was 1.93mmol/L. This is an important trial as it provides new evidence that an additional therapy that is not primarily focused on LDL cholesterol reduction can lower cardiovascular risk further. Table 3. The known knowns Treat LDLC (or apob/non-hdlc) aggressively Lower LDL cholesterol is better Statin therapy ± ezetimibe ± PCSK9i Severe hypertriglyceridaemia (TG >mmol/l) Fibrates to prevent pancreatitis Normal TG, normal HDLC No fibrates for atherosclerosis prevention 2013; (11): Aung T, Halsey J, Kromhout D, et al. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. Meta-analysis of Trials Involving Individuals. JAMA Cardiol 2018; 3(3): doi:.01/jamacardio Genuth S, Ismail Beigi F. Clinical implications of the ACCORD trial. J Clin Endocrinol Metab. 2012; 97(1): Find us at DeNovo Disclaimer The views and opinions expressed in the article are those of the presenters and do not necessarily reflect those of the publisher or its sponsor. In all clinical instances, medical practitioners are referred to the product insert documentation as approved by relevant control authorities. Published by denovo Medica Reg: 2012/216456/07 70 Arlington Street, Everglen, Cape Town, 7550 Tel: (021) I info@denovomedica.com 6 I November 2018
Zuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationHypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC
Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and
More informationMetabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD
Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy
More informationChallenges in type 2 diabetes control: slipping control and weight gain
control Earn 3 CPD Points online Case study Challenges in type 2 diabetes control: slipping control and weight gain Presenter Dr Sedeshan Govender Specialist Physician, Endocrinologist and Diabetologists
More informationDyslipidemia. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan
Dyslipidemia Objectives: Not given. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan Team Leader: Amal Alshaibi Revised By: Yara Aldigi and Basel almeflh Resources: 435
More informationDyslipidemia. (Med-341)
Dyslipidemia (Med-341) Anwar A Jammah, MD, FRCPC, FACP, CCD, ECNU. Associate Professor of Medicine Consultant Medicine, Endocrinology, Thyroid Oncology Department of Medicine, King Saud University The
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Lipid disorders: Disorders of lipid metabolism are manifest by elevation of the plasma concentrations of the various lipid and lipoprotein fractions (total and LDL cholesterol,
More informationRoyal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease
Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines 1 This guideline is intended to assist rational and cost-effective prescribing of lipid regulating medications across both primary and
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationHypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002
Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationAntihyperlipidemic drugs
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationLipids Board Review. Ira Goldberg, MD New York University School of Medicine. Which of the following is the best initial therapy choice?
Lipids Board Review Ira Goldberg, MD New York University School of Medicine 1. A 22 year old male college student is referred for severe hypertriglyceridemia ( 1500 mg/dl [ 17.0 mmol/l]). He has a history
More informationATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS
LABORATORY AND RISK FACTORS OF ATHEROSCLEROSIS S R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty RISK FACTORS FOR CHD Clinical Risk Factors Laboratory Risk Factors MAJOR CLINICAL RISK
More informationDeath is inevitable but premature death is not. Sir Richard Doll
Welcome to the Diabetes Care for You webinar Please log onto the conference call so you can hear our presenter From any SCFT Cisco phone dial 800800 From a mobile phone or any other phone dial 01273 242
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationSouthern Derbyshire Shared Care Pathology Guidelines. Dyslipidaemia
Southern Derbyshire Shared Care Pathology Guidelines Dyslipidaemia This guideline applies to patients with significantly abnormal lipid profiles, which may be primary (genetic), secondary to other diseases
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationIdentification and management of familial hypercholesterolaemia (FH) - An overview
Identification and management of familial hypercholesterolaemia (FH) - An overview National Collaborating Centre for Primary Care and Royal College of General Practitioners NICE Guideline CG 71 (August
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationBioresorbable polymer drug-eluting stents in PCI
EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed
More informationVolume 2; Number 11 July 2008
Volume 2; Number 11 July 2008 CONTENTS Page 1 NICE Clinical Guideline 67: Lipid Modification (May 2008) Page 7 NICE Technology Appraisal 132: Ezetimibe for the treatment of primary (heterozygous familial
More informationFORTH VALLEY. LIPID LOWERING GUIDELINE v5 2016
FORTH VALLEY LIPID LOWERING GUIDELINE v5 2016 This guideline applies to people over 16 years of age. This guideline is not intended to serve as a standard of medical care or be applicable in every situation.
More informationAnti Hyperlipidemic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anti Hyperlipidemic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Lipoproteins Macromolecular complexes in the blood that transport lipids Apolipoproteins
More informationLowering lipid-related cardiovascular (CV)
DYSLIPIDAEMIA Earn 3 CPD Points online This article was made possible by an unrestricted educational grant by Cipla Medpro, who had no control over content. Effective management of dyslipidaemia A summary
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationPrimary Prevention Patients aged 85yrs and over
Rotherham Guideline for the management of Non-Familial Hypercholesterolaemia Type 1 Diabetes Offer lifestyle advice Over 40yrs of age? Diabetic for more than 10 years? Established nephropathy? Other CVD
More informationPodcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam
Podcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam Howard J. Sachs, MD www.12daysinmarch.com Email: Howard@12daysinmarch.com Podcast (Video Recorded
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACC/AHA. See American College of Cardiology/ ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors American College of Cardiology/American
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More information10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk?
Lessons Learned from Tim Russert: Investigating Residual Risk Peter H. Jones, MD, FACP Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Houston, Texas Tim Russert:
More informationBACKGROUND: The association between
DOI: 10.18585/inabj.v9i1.266 Association between Cardiovascular Risk and Elevated Triglycerides (Sargowo D, et al.) REVIEW ARTICLE The Association between Cardiovascular Risk and Elevated Triglycerides
More informationPediatric Dyslipidemia: Angela Gooden MSN, RN, CPNP- AC/PC, Texas Children s Hospital, Pediatric Cardiology
Pediatric Dyslipidemia: Angela Gooden MSN, RN, CPNPAC/PC, Texas Children s Hospital, Pediatric Cardiology Objectives Define pediatric dyslipidemia Describe the association between pediatric dyslipidemia
More informationcolds and flu Introduction KEY MESSAGES
colds and flu New insights: Cold and flu Introduction Colds and flu are responsible for more visits to the pharmacy than any other infectious illness. While severity of influenza differs from year to year,
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationCase Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic
Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for
More informationDrug regulation of serum lipids
Drug regulation of serum lipids Foundations of Biomedical Science MEDS90001 Dr Michelle Hansen Pharmacology & Therapeutics mjhansen@unimelb.edu.au References Katzung, Basic & Clinical Pharmacology Ch 35
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationpremix insulin and DPP-4 inhibitors what are the facts? New Sit2Mix trial provides first global evidence
Earn 3 CPD Points online Using a premix insulin (BIAsp 30) with a DPP-4 inhibitor what are the facts? New Sit2Mix trial provides first global evidence An important trial using a premix insulin (BIAsp 30)
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationHypertriglyceridemia, Inflammation, & Pregnancy
Hypertriglyceridemia, Inflammation, & Pregnancy Richard L. Nemiroff, MD, FACOG, NLA Professor, Clinical Gynecology Perelman School of Medicine University of Pennsylvania Philadelphia, PA Disclosure of
More informationConsiderations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction
Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationClassification. Etiology
Dyslipidemia Dyslipidemia is the elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high-density lipoprotein level that contributes to the development of atherosclerosis. Causes may
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationHyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE
Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationUse of Subgroups to Rescue a Trial or Improve Benefit-Risk
1 Use of Subgroups to Rescue a Trial or Improve Benefit-Risk Martin King, Ph.D. Director, Statistics Global Pharmaceutical R&D, Abbott Abbott Park, IL USA 2 Disclaimer The opinions in this presentation
More informationDYSLIPIDEMIA RECOMMENDATIONS
DYSLIPIDEMIA RECOMMENDATIONS Α. DIAGNOSIS Recommendation 1 INITIAL LIPID PROFILING (Level of evidence II) It is recommended to GPs and other PHC Physicians to assess the lipid profile {total cholesterol
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationCoronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol)
CLINICAL GUIDELINE Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol) A guideline is intended to assist healthcare professionals in the choice of disease-specific
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationNature Genetics: doi: /ng.3561
Supplementary Figure 1 Pedigrees of families with APOB p.gln725* mutation and APOB p.gly1829glufs8 mutation (a,b) Pedigrees of families with APOB p.gln725* mutation. (c) Pedigree of family with APOB p.gly1829glufs8
More informationCLINICAL IMPORTANCE OF LIPOPROTEINS
25 Hyperlipidemias CLINICAL IMPORTANCE OF LIPOPROTEINS Raised levels of low-density lipoprotein (LDL) cholesterol and low levels of high density lipoprotein (HDL) cholesterol are independent risk factor
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationRecent Advances & Emerging Data in the Treatment of Hypertriglyceridemia. Michael Miller, MD, FACC, FAHA, FNLA
Recent Advances & Emerging Data in the Treatment of Hypertriglyceridemia Michael Miller, MD, FACC, FAHA, FNLA Professor of Medicine, Epidemiology & Public Health University of Maryland School of Medicine
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationClinical Practice Guideline
Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)
More informationCardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationMetabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology
Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient
More informationChapter (5) Etiology of Low HDL- Cholesterol
Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Cardiovascular disease (CVD) is responsible for one-third of global deaths and is a leading and increasing contributor to the
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationNorth Americans consume 100 g of fat per day on
PRACTICE AT THE BEDSIDE Common problems in the management of hypertriglyceridemia Michelle A. Fung, Jiri J. Frohlich Case A 41-year-old man presents for assessment of severe hypertriglyceridemia. He has
More informationProspective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
More informationAPPENDIX 2F Management of Cholesterol
Patients with established CVD: Coronary heart disease Cerebrovascular disease Peripheral vascular disease APPEDIX 2F Management of Cholesterol Patients at high risk of cardiovascular events: Chronic kidney
More informationTopic 11. Coronary Artery Disease
Topic 11 Coronary Artery Disease Lipid metabolism http://news.bbc.co.uk/2/hi/health/7372495.stm Sterol Metabolism and Coronary Artery Disease Big Picture: Exogenous Cholesterol and Fat Metabolism Fats-Triglycerides
More informationDyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Dyslipidemia and HIV Heidi Crane, MD, MPH Madison Metabolic Clinic Associate Professor UW Department of Medicine Presentation prepared by: Heidi Crane, MD,
More informationA guide to cholesterol and heart disease for people with diabetes
A guide to cholesterol and heart disease for people with diabetes Assisted by Developed and Sponsored by Pfizer The charity for people with diabetes Assisted by Pfizer Limited 2005. All rights reserved.
More informationLatest Nutritional Guidelines: What s new for practice? Paul Pipe-Thomas Specialist Dietitian
+ Latest Nutritional Guidelines: What s new for practice? Paul Pipe-Thomas Specialist Dietitian + Evidence Based Guidelines Last nutritional guidelines published in 2003. New guidelines published in May
More informationThe Role of Apolipoprotein CIII in Coronary Artery Disease. Disclosures
Miami Cardiac & Vascular Institute Cardiovascular Disease Prevention 15th Annual Symposium February 16, 2017 Nobu Eden Roc Hotel, Miami Beach, Florida. The Role of Apolipoprotein CIII in Coronary Artery
More informationLearning Objectives. Cholesterol and Lipids in Kids: It s a Matter of the Heart. Is Atherosclerosis a Pediatric Disease?
Scott J. Soifer, MD Professor and Vice Chair Department of Pediatrics University of California, San Francisco UCSF Benioff Children s Hospital Cholesterol and Lipids in Kids: It s a Matter of the Heart
More informationImbalances in lipid components
Drugs for Dyslipidemia Vivien Gam, Pharm.D. 1 Dyslipidemia Imbalances in lipid components High total cholesterol High LDL cholesterol Low HDL cholesterol High triglycerides Significant risk factor for
More informationTreatment of Atherosclerosis in 2007
Treatment of Atherosclerosis in 2007 Szilard Voros, M.D. Medical Director Cardiovascular MR and CT Piedmont Hospital, Piedmont Hospital Our Paradigm Genotype Phenotype Environment Atherosclerotic Disease
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More informationMacrovascular Management. What s next beyond standard treatment?
Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk
More informationDYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role
More informationBIOCHEMISTRY BLOOD - SERUM Result Range Units
BIOCHEMISTRY BLOOD - SERUM Result Range Units LIPIDS CHOLESTEROL 3.9 0.0-5.5 mmol/l TRIGLYCERIDES 0.7 < 1.5 mmol/l LIPID STUDIES HDL(Protective) 1.5 > 1.2 mmol/l LDL(Atherogenic) 2.1 0.5-3.5 mmol/l Cholesterol/HDL
More informationThis is a lipid lowering drug strategy which should only be used within an overall lifestyle and clinical management strategy.
Treatment Guideline Statin Prescribing Objective These guidelines represent the views of the Gloucestershire Hospitals NHS Foundation Trust, which were arrived at after consideration of the available evidence
More informationManaging Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus
Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Council and Section The Medical University
More informationCentral role of apociii
University of Copenhagen & Copenhagen University Hospital Central role of apociii Anne Tybjærg-Hansen MD DMSc Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen,
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationLecture 36 Dyslipidemia Therapeutics Barry LIPIDS:
LIPIDS: PATHOPHYSIOLOGY: TC or LDL-C = CVD HDL-C = CVD Association between TG and CVD not established o HyperTG associated with pancreatitis o Reducing TG w/ drug therapy doesn t CVD TYPES OF DYSLIPIDEMIA:
More informationMMBS, MMED (Path),MAACB, MACTM, MACRRM
Dr Mere Kende MMBS, MMED (Path),MAACB, MACTM, MACRRM Lecturer- SMSH Brief Overview of Lipids What is dyslipidemia? Classification of hyperlipidemia Primary vs secondary hyperlipidemia Hypercholesterolaemia
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationFacts on Fats. Ronald P. Mensink
Facts on Fats Ronald P. Mensink Department of Human Biology NUTRIM, School for Nutrition, Toxicology and Metabolism Maastricht University Maastricht The Netherlands Outline of the Presentation Saturated
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More information